The Radnor biopharmaceutical firm Mineralys Therapeutics saw its stock price hit new heights Monday after a positive ...

Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced positive topline results from its pivotal Launch-HTN Phase 3 and ...

A Radnor biopharma firm saw its stock price skyrocket after the company posted positive late-stage clinical trial results for ...

BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering. LifeSci Capital is acting as lead manager and H.C.

Mineralys Therapeutics enjoyed a big stock bump after its aldosterone synthase inhibitor chalked up wins in two types of ...

The deal size was reduced to $175M from $250M and priced below last closing price of $14.30. BofA, Evercore ISI, Goldman Sachs, Stifel and ...

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) released topline data from its pivotal Launch-HTN Phase 3 and pivotal Advance-HTN ...

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea ...

Two pivotal trials of the aldosterone synthase inhibitor have shown positive results for lorundrostat in uncontrolled and ...

Primary endpoints of both Advance-HTN and Launch-HTN studies, using lorundrostat to treat patients with hypertension were met ...

Findings from a pair of studies in tough-to-treat hypertension establish Mineralys’ drug as a “derisked, almost-commercial ...

Mineralys Therapeutics, Inc. has a 12 month low of $8.24 and a 12 month high of $18.29. The stock has a market cap of $712.65 million, a P/E ratio of -3.93 and a beta of 1.50.